Scarica l'app Stockscreener
119.50
0.61%
0.72
Pre-mercato:
120.00
0.50
+0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Aigen Investment Management LP Purchases Shares of 4,663 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Investment Analysts’ Recent Ratings Updates for Axsome Therapeutics (AXSM) - Defense World
Lindbrook Capital LLC Lowers Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Brokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $167.36 - MarketBeat
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing - MSN
How to Take Advantage of moves in (AXSM) - Stock Traders Daily
HC Wainwright Reiterates Buy Rating for Axsome Therapeutics (NASDAQ:AXSM) - Defense World
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals - MSN
Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025 - MSN
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online
Axsome Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Torray Investment Partners LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given New $160.00 Price Target at Robert W. Baird - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by New York State Common Retirement Fund - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by US Bancorp DE - MarketBeat
Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright maintains Axsome stock Buy rating, $200 target By Investing.com - Investing.com Canada
Axsome Therapeutics: Strategic Developments and Market Exclusivity Drive Buy Rating - TipRanks
H.C. Wainwright maintains Axsome stock Buy rating, $200 target - Investing.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of “Buy” by Analysts - Defense World
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Axsome settles patent litigation with Hikma over Sunosi By Investing.com - Investing.com Canada
Axsome Therapeutics gets FDA support to submit sNDA for its Alzheimer’s disease agitation treatment - MSN
Axsome resolves patent dispute with Hikma - MSN
Axsome Therapeutics Resolves Sunosi Patent Case With Hikma -March 05, 2025 at 08:08 am EST - Marketscreener.com
Axsome stock gains asHikma patent feud ends (AXSM:NASDAQ) - Seeking Alpha
Axsome Settles Patent Litigation With Hikma Related To SunosiQuick Facts - Nasdaq
Axsome settles patent litigation with Hikma over Sunosi - Investing.com India
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA - The Manila Times
Axsome Wins 16+ Years of Market Exclusivity for Sunosi in Patent Settlement - StockTitan
Robert W. Baird Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - Defense World
Axsome Therapeutics (NASDAQ:AXSM) Receives Buy Rating from Needham & Company LLC - Defense World
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $190.00 - MarketBeat
Axsome Therapeutics expects to submit sNDA for AXS-05 in Q3 - TipRanks
Axsome Therapeutics Receives FDA Indication in Support of Alzheimer's Drug Submission - Marketscreener.com
Axsome Therapeutics set for 3Q sNDA submission for AXS-05 - Investing.com
Axsome's Alzheimer's Agitation Drug Clears Critical FDA Hurdle After Triple Trial Success - StockTitan
New York State Common Retirement Fund Purchases 8,843 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
2.14%
2.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):